News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Hutchison China MediTech (Chi-Med) Reports Positive Data From Phase I Trial Of Syk Inhibitor



11/18/2016 9:46:41 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Hutchison China MediTech (Chi-Med) reported positive data from a first-in-human Phase I trial of HMPL-523, a Syk inhibitor. Syk helps to regulate downstream signaling in immune receptors, including B cell receptors. Chi-Med expects to test the candidate as a treatment for rheumatoid arthritis and B-cell malignancies. In healthy volunteers, the Phase I trial of HMPL-523 showed the molecule was generally well-tolerated and suppressed B-cell activation in a dose-dependent manner.

Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES